Home › FDA Approves Mercks NOXAFIL (posaconazole) Delayed-Release Tablets
 

Keywords :   


FDA Approves Mercks NOXAFIL (posaconazole) Delayed-Release Tablets

2013-11-26 15:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Language: English Contact: MerckMedia Contacts:Pam Eisele, 908-423-5042Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: tablets fda approves fda approves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
09.11Atlantic Tropical Weather Outlook
09.11Eastern North Pacific Tropical Weather Outlook
08.11Hurricane Rafael Graphics
08.11Hurricane Rafael Wind Speed Probabilities Number 22
08.11Hurricane Rafael Forecast Advisory Number 22
08.11Hurricane Rafael Public Advisory Number 22
08.11Summary for Hurricane Rafael (AT3/AL182024)
08.11Trump tariffs could cost UK 22bn of exports
More »